×

Time to buy these oil stocks

Jim Cramer often teaches investors about game changing elements of the stock market that can impact a portfolio. He has spoken in the past about everything from earnings to commodity prices, but this time he sees something different. This is one thing that could bring down the entire market, and perhaps change history.

The deadliest trend out there is supply. And for the longest time, there hasn't been a ton of it. We currently have approximately half the amount of IPO deals that we had last year at this time. Companies seemed to have a big appetite for their own stock, and buybacks have become a staple.

Wednesday marked the first day of a trend that could change the game and kiss the value of stocks goodbye. Cramer saw a flood of stocks deals from companies that offered shares that investors didn't want, or required investors to liquidate other stocks so they can buy new ones.

"The stock market is like a department store that can only stock so much merchandise. At a certain point…you have to discount the existing merchandise to get it to move," Cramer said.

The plethora of IPOs from companies like Etsy and GoDaddy with questionable fundamentals, and secondary deals form companies like Abbott Laboratories that worried Cramer the most. He wouldn't be so worried about these deals normally. But they are coming in right after seven offerings from seven biotech companies that have lost money over the years. It's too much!

Granted, no April has ever been down in the third year of a sitting president. Cramer is aware of this, and agrees that the market could be due for a bounce after Friday's key employment numbers come out.

But in the end, the biggest enemy of a bull market is supply. Cramer can't ignore the fact that there is an overwhelming amount of it right now, and wants to make sure this is on the radar of investors as we begin a new quarter.

Read MoreCramer: Watch out! Market's No.1 enemy right now

oil crude gas
Getty Images

One of the trends that Cramer has been encouraging investors to get in on is the organic and natural movement that has swept the country. Cramer fave stocks like WhiteWave and Hain Celestial have also showed the love back to investors wallets, too.

But why only restrict the movement to humans? Freshpet is a small-cap speculative stock that is right in the intersection of this trend. It sells all natural meat based pet food that has been minimally processed. Don't bother looking for it on the shelves at the grocery store, because it's refrigerated—just like human food!

On Tuesday the company reported a strong quarter with in line earnings and higher than expected revenues, up 38.4 percent year over year. Can it keep climbing? To find out, Cramer sat down with Freshpet CEO Richard Thompson.

"I think we're still in the first inning. This is a $20 billion market and I'm going to take my $1 billion. We are growing, and you can see any time you have a brightly lit colorful fridge that stops consumers in the store, then we've got something to talk about," Thompson said.

Another hot topic that garnered major attention from the "Mad Money" host, is how resilient the oil market is. Black gold managed to stand its ground on Wednesday and had a nice bounce in price, despite the fact that crude inventories showed a buildup of supply.

"Something has clearly changed and changed for the better," the "Mad Money" host said.

And while Cramer does have a bearish forecast on oil stocks for the long-term, he can't help but acknowledge some of the good things happening right now.

"The most important thing you need to know about these stocks is that the expectations are low, so low, in fact, that they could be beaten," Cramer said.

There have been various secondary offerings that have been brought to the market that managed to pull off some pretty snazzy returns. For instance,Carrizo priced a big chunk of stock at $45 a share and it now trades at $50. Likewise, Concho Resources offered a deal at about $112 a share, and it's now trading at $118. Those are just a few of the deals that had Cramer salivating.

Cramer recommended that it is time to jump in and buy oil or oil service companies. He even snapped up some Schlumberger for his charitable trust, and can't wait to expand the position.

"There are just way too many positives developing here, in a group where people have gotten too negative," he added.

Read MoreCramer: Oil patch is ready for buyers again

Robert Finizio, CEO of TherapeuticsMD
Scott Mlyn | CNBC
Robert Finizio, CEO of TherapeuticsMD

Most of the small speculative biotech stocks were slammed last week hard, but now that the economy has slowed down a bit in the second quarter, Cramer took the time to circle back to an interesting pharma company that could present a new angle on women's health.

TherapeuticsMD is a pharmaceutical company geared towards specialization of hormone replacement therapies. And while it does also have a sideline business in prenatal vitamins, its main focus is to create formulations that deal with complications of menopause.

Could this angle on women's health bring in major bucks for investors? To find out, Cramer sat down with TherapeuticsMD co-founder and CEO Robert Finizio.

The CEO explained that during menopause, women's ovaries stop producing both estrogen and progesterone. The reduction in estrogen can cause effects for women, such as hot flashes. Currently the only FDA approved products available are synthetic.

A large study recently conducted on women showed that synthetic hormones are linked to an increase risk of cancer, especially breast cancer.

"The problem that we look to solve is that there is no FDA approved natural hormone combination. We are the first people to put that into phase one, phase two and phase three," Finizio said.

Read More Cramer: Huge pharma opportunity for women's health

In the Lightning Round, Cramer gave his take on a few caller favorite stocks:

Insys Therapeutics: "Good company, makes money but be careful because Johnson & Johnson has a pain management thing brewing that I think could put a lot of products not in a strong position. Mallinckrodt has a great pain franchise, and that's another stock that I like very much."

Dunkin' Brands Group: "I'm not a fan. I'm a fan of the coffee, and I love my Dunkin' Donuts, I think it's terrific and I like its coffee because it's real hot but the stock I think has stalled in the mid $40s. I like growth and I don't think they have the growth. They missed the numbers a couple of times...I don't want good tasting donuts, I want earnings per share growth!"

Read MoreLightning Round: Be careful—this lurks everywhere